Abstract
Chronic kidney disease (CKD) is frequently complicated by the coexistence of cardiovascular (CV) events, making it essential to identify CV risk in CKD. Serum cystatin-C is an upcoming renal biomarker, which is used to measure estimated glomerular filtration rate (eGFR) by the CKD-EPI formula.
Highlights
Chronic kidney disease (CKD) is a world-wide health problem whose burden continues to increase
Serum cystatin-C based estimated glomerular filtration rate (eGFR) was found to be better correlated with the lipid profile, when compared with eGFR estimation using serum creatinine
The correlation between cystatin-C based eGFR and lipids might indicate that this eGFR methodology may be a better marker of cardiovascular risk as lipids are a well known traditional risk factor for cardiovascular disease
Summary
Chronic kidney disease (CKD) is a world-wide health problem whose burden continues to increase. CKD encompasses a spectrum of different pathophysiologic processes, associated with abnormal kidney function and a progressive decline in glomerular filtration rate (GFR). The National Kidney Foundation had provided a classification for chronic kidney diseases, which has since evolved through time. This staging of chronic kidney disease, as delineated by the Kidney Dialysis Outcomes Quality Initiative (KDOQI), depends on the estimated glomerular filtration rate (eGFR) [1]. Serum creatinine is the most commonly used marker for eGFR using the Cockcroft-Gault formula or the MDRD (Modification of Diet in Renal Disease) [3]. Serum cystatin-C is an upcoming renal biomarker, which is used to measure estimated glomerular filtration rate (eGFR) by the CKD-EPI formula
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
